News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-05-06-2015
Volume11
Issue 5

Capsugel Produces DPI Phase 2 Trial Supplies

Capsugel extends inhaled biotherapeutics delivery capability to Phase 2 clinical trials.

 

Capsugel announced on May 4 that the company has manufactured Phase 2 clinical trial supplies for a dry powder inhalation (DPI) formulation that delivers biotherapeutics to the lung. The supplies were manufactured by Bend Research, part of Capsugel’s Dosage Form Solutions business unit.

The inhaled dry-powder biotherapeutic, which was developed using particle engineering and spray-drying processing methods, is the first inhalation delivery therapy to be manufactured to Phase 2 scale at the company’s clinical trial manufacturing facility in Bend, OR.

The spray-dry technology and particle engineering provides a stable dry powder with improved aerosol performance and high collection efficiencies, the company reports. The DPI powders will be dosed in a Phase 2 clinical trial in 2015.

Capsugel reports that it will add commercial spray-drying capacity this year, enabling the company to manufacture DPI formulations at commercial scale.

Source: Capsugel

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com